CatalystFDA/Bio

Sanofi (ENXTPA:SAN) Permanently Halted Its Phase 3 Infant RSV Vaccine Trial

Phase 3 trial permanently halted signals major clinical setback for Sanofi’s RSV vaccine.

What changed

Phase 3 trial permanently halted signals major clinical setback for Sanofi’s RSV vaccine.

Why it matters

Phase 3 trial permanently halted signals major clinical setback for Sanofi’s RSV vaccine. — impact context not separately stored; see What changed.

Sources